Introduction
============

Every year, approximately 5--15% of the world's population are infected with influenza virus ([@B45]). Of the three types of influenza virus (A, B, and C), influenza A virus is the most common cause of respiratory illnesses in humans. Influenza A virus typically causes an acute and self-limiting infection characterized by symptoms such as myalgia, fever, and a dry cough. However, in patients with one or more underlying medical conditions, influenza A virus can cause severe, and even fatal, disease ([@B49]). Influenza thus represents a significant healthcare challenge for the 21st century, where the majority of people have more than one medical ailment ([@B59]). This interaction between chronic disease and influenza was particularly evident after the 2009 H1N1 influenza pandemic ([@B26]). Specifically, this pandemic highlighted that people with diabetes suffered from more severe influenza than people with no underlying medical condition ([@B2]; [@B60]). Here, we review the currently available literature on the role of diabetes in the pathogenesis of influenza virus. We further highlight the specific roles that high, and/or oscillating, blood glucose levels may play in the severity of influenza virus.

Diabetes Mellitus and its Vascular Complications
================================================

Diabetes mellitus affects 415 million people worldwide and this figure is projected to increase to 642 million by the year 2040 ([@B22]). Diabetes is characterized by chronic hyperglycemia and is classified into two main types. Type 1 diabetes accounts for approximately 10% of all cases and is most commonly caused by an autoimmune condition affecting insulin production. In contrast, type 2 diabetes accounts for approximately 85--90% of cases and is characterized by insulin resistance and compromised insulin secretory capacity. All individuals with diabetes have an increased risk of developing a number of serious complications. Diabetes is a leading cause of blindness, limb amputations, end-stage kidney failure, and cardiovascular disease ([@B55]). Chronic hyperglycemia is thought to underlie the development of complications and, as such, a primary aim in the management of diabetes is to improve blood glucose control ([@B12]). Blood glucose control is typically assessed by measuring a patient's HbA1c. The term HbA1c refers to glycated hemoglobin, i.e., when hemoglobin joins with glucose and becomes 'glycated.' The average lifespan of red blood cells is approximately 2--3 months, meaning that HbA1c provides an estimate of long-term blood glucose control. Interestingly, however, there is no guarantee that achieving near-normal HbA1c levels (HbA1c \< 7%), particularly in patients with long-standing type 2 diabetes, will prevent the onset and progression of vascular complications. Using traditional therapies, such as metformin, sulphonylureas and insulin, near-normal HbA1c levels were achieved in numerous trials but mortality from cardiovascular disease was either not affected ([@B56]; [@B54]; [@B11]) or increased ([@B53]). In the latter study, the trial was prematurely stopped due to a significant increase in short-term mortality following intensive glucose lowering ([@B53]). The lack of a definitive conclusion in this field has dampened clinical urgency to normalize HbA1c levels and suggests that other factors may contribute to the development of diabetic complications.

Influenza Virus in Diabetes Mellitus
====================================

Prior to the 2009 H1N1 pandemic, several studies had already suggested that diabetes enhanced the severity of influenza ([@B10]; [@B57]). [@B57] showed that from 1986 to 1989, people with diabetes were more likely to have pneumonia and influenza recorded on their death certificate than people without diabetes. However, the most extensive body of evidence regarding this relationship emerged following the first influenza pandemic of the 21st century: the 2009 H1N1 pandemic. Numerous clinical studies suggested that people with diabetes were a key susceptibility group for severe H1N1 infections (see **Table [1](#T1){ref-type="table"}**). For example, in Canada, diabetes tripled the risk of hospitalization after infection with the 2009 H1N1 virus and quadrupled the risk of admission to the intensive care unit ([@B2]). Similarly, in Germany, diabetes doubled the risk of a fatal outcome after infection with the 2009 virus ([@B60]). Whilst the majority of clinical studies suggest a role for diabetes in increasing influenza severity, this synergism was not observed in all studies (see **Table [1](#T1){ref-type="table"}**). Taken together, these data suggest that the relationship between diabetes and influenza may vary depending on the diabetic patient population in question. It is also important to note that many patients with diabetes have various other conditions that can increase (or decrease) the severity of influenza. For example, approximately 90% of patients living with type 2 diabetes are overweight, and obesity is an independent risk factor for severe influenza ([@B33]). Adjusting clinical analyses for the presence of these other illnesses has yielded contradictory results (see **Table [1](#T1){ref-type="table"}**), highlighting the need for further research in this area. Nevertheless, consistent with the majority of clinical observations, murine models demonstrate that diabetes increases susceptibility to severe infections with both seasonal and highly pathogenic influenza virus strains (see **Table [2](#T2){ref-type="table"}**).

###### 

The role of diabetes in the severity of 2009 pandemic influenza.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year/s observed                 Country                                Sample size (% diabetes^1^)   Diabetes type^2^   Primary outcome(s) measured   Results^3^                                      Findings/conclusions                                                                                                                                  Reference
  ------------------------------- -------------------------------------- ----------------------------- ------------------ ----------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  April 2009 -- June              USA^4^                                 668 (2%)                      n/a                Hospitalization               ND: 311/658 (47%), D: 5/10 (50%)                Diabetes did not affect the rate of                                                                                                                   [@B13]

  2010                                                                                                                    ICU admission                 ND: 114/658 (17%), D: 2/10 (20%)                hospitalization or ICU admission                                                                                                                      

  1 January -- 1 December 2009    Spain                                  11,499 (9%)                   97 Type I\         Death                         ND: 244/10,416 (2%), D: 38/1,033 (4%)           No difference in fatality risk in any age group between those with and without diabetes                                                               [@B24]
                                                                                                       936 Type II                                                                                                                                                                                                                                            

  16 April -- 30 August 2009      Canada                                 716 (7%)                      n/a                Hospitalization\              ND: 283/666 (43%), D: 38/50 (76%)\              Diabetes was associated with an increased risk of hospitalization.                                                                                    [@B15]
                                                                                                                          ICU admission\                ND: 39/666 (6%), D: 8/50 (16%)\                                                                                                                                                                       
                                                                                                                          Death                         ND: 12/666 (2%), D: 3/50 (6%)                                                                                                                                                                         

  26 April -- 26                  Canada                                 1,479 (9%)                    n/a                Non-severe outcome            ND: 1,089/1,342 (81%), D: 82/137 (60%)          The risk of a severe outcome was                                                                                                                      [@B6]

  September 2009                                                                                                          Non-fatal ICU admission\      ND: 194/1,342 (15%), D: 42/137 (31%)\           greatest among patients with\                                                                                                                         
                                                                                                                          Death                         ND: 59/1,342 (4%), D: 13/137 (10%)              diabetes                                                                                                                                              

  1 May -- 31 December 2009       USA                                    66 (32%)                      n/a                ICU admission                 ND : 19/45 (42%), D: 10/21 (48%)                No difference in pre-existing comorbidities between ICU and non-ICU patients                                                                          [@B58]

  25 May -- 1 July 2009           Canada                                 162 (13%)                     9 Type I\          ICU admission                 ND: 21/140 (15%), D: 10/22 (45%)                Diabetes tripled the risk of hospitalization and quadrupled the risk of ICU admission once hospitalized                                               [@B2]
                                                                                                       13 Type II                                                                                                                                                                                                                                             

  12 June -- 5 December 2009      Spain                                  304 (50%)                     n/a                ICU admission\                ND: 69/252 (27%), D: 97/252 (38%)\              Worse outcomes in patients with diabetes may be a consequence of the higher prevalence of underlying medical conditions rather than diabetes itself   [@B8]
                                                                                                                          Death                         ND: 15/252 (6%), D: 30/252 (12%)                                                                                                                                                                      

  24 July 2009 -- 3 March 2010    French West Indies and French Guiana   241 (3%)                      n/a                Severe infection\             ND: 27/234 (12%), D: 3/7 (43%)\                 Diabetes was associated with a higher risk of severe influenza                                                                                        [@B4]
                                                                                                                          Death                         ND: 30/234 (13%), D: 0/7 (0%)                                                                                                                                                                         

  1 October -- 23 December 2009   China                                  155 (13%)                     n/a                Death                         ND: 20/128 (16%), D: 7/20 (35%)                 Diabetes is likely to be an additional risk factor compared to obesity alone                                                                          [@B63]

  November 2009 -- January 2010   France                                 1,266 (10%)                   n/a                ICU admission\                Diabetes was a risk factor for ICU admission\   Diabetes is likely to be an additional risk factor compared to obesity alone for ICU admission but not death                                          [@B17]
                                                                                                                          \                             ND: 241/1139 (21%), D: 34/127 (27%)                                                                                                                                                                   
                                                                                                                          Death                                                                                                                                                                                                                               

  March -- December 2010          Brazil                                 4,740 (2%)                    n/a                Hospitalization               ND: 1,948/4,632 (42%), D: 72/108 (67%)          Diabetes was identified as a risk factor for hospitalization                                                                                          [@B28]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1

Percentage rounded to nearest whole number.

2

n/a: Diabetes type was not specified.

3

D: Patients with diabetes; ND: Patients without diabetes.

4

Patients aged 18 years or younger.

###### 

Animal models of diabetes and influenza.

  Mouse model                                      Diabetes type modeled   Influenza A virus subtype   Measure of disease severity        Findings                                                                                                                                                                                                                           Reference
  ------------------------------------------------ ----------------------- --------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  STZ-induced diabetes in BALB/c mice              I                       H1N1                        Lung viral titers Lethal dose 50   Diabetic mice had increased influenza virus titers and a lower lethal dose 50 compared to non-diabetic mice.                                                                                                                       [@B65]
  STZ-induced diabetes in BALB/c mice              I                       H5N1                        Lung viral titers Lethal dose 50   Diabetic mice had increased influenza virus titers, a lower lethal dose 50 and a more persistent viral infection compared to non-diabetic mice.                                                                                    [@B62]
  RIP-K^b^ transgenic diabetic mice                I                       H3N2                        Lung viral titers Weight loss      There was a significant correlation between blood glucose levels and influenza virus titers in diabetic mice. Diabetic mice had increased influenza virus titers but no difference in weight loss compared to non-diabetic mice.   [@B41]
  BKS.Cg-+*Lepr*db/+*Lepr*db/Jcl (diabetic mice)   II                      H1N1                        Lethal dose 50 Death               Diabetic mice had a lower lethal dose 50 and a higher mortality rate compared to non-diabetic mice.                                                                                                                                [@B23]

A Role for Hyperglycemia
========================

At present, the mechanisms by which diabetes can increase the severity of influenza remain unclear. There is a growing body of evidence that hyperglycemia can increase the incidence and severity of bacterial infections. For example, diabetic patients with an HbA1c level \> 7% had a three times increased risk of active tuberculosis compared to those with an HbA1c level \< 7% ([@B29]). Similarly, diabetic patients with hyperglycemia (\>7% HbA1c) were more likely to develop *Klebsiella pneumoniae* liver abscess than diabetic patients with controlled glycaemia ([@B30]). It has also been reported that individuals with diabetes are more likely to suffer from infection-related mortality following a kidney allograft than non-diabetic patients ([@B18]). However, in a recent systematic review of a range of surgical specialities, the relationship between preoperative HbA1c levels and postoperative complications, including mortality from infection, was less convincing ([@B43]). The authors noted that their retrospective analyses contained heterogenous datasets of small sample sizes and that further research, specifically dedicated to addressing this topic, is warranted ([@B43]).

With regards to respiratory tract infections, [@B40] noted a striking positive correlation with the mean plasma glucose levels in patients with diabetes. These findings may reflect, in part, the immunosuppressive effects of hyperglycemia. Hyperglycemia can reduce neutrophil degranulation ([@B51]), impair complement activation ([@B21]) and impair phagocytosis ([@B1]) -- all of which can increase the severity of bacterial infections as well as viral infections such as influenza. However, to date, there have been only limited experimental studies directly addressing the role of hyperglycemia in the pathogenesis of influenza virus.

Elevated blood glucose levels can directly increase glucose concentrations in airway secretions ([@B36]). *In vitro* exposure of pulmonary epithelial cells to elevated glucose concentrations significantly increased influenza virus infection and replication ([@B25]), suggesting that hyperglycemia may increase viral replication *in vivo*. Elevated glucose levels may also serve to suppress the anti-viral immune response ([@B41]). In a mouse model of type I diabetes, susceptibility to influenza was associated with a reduction in the anti-viral activity of collectins ([@B41]). This immunosuppression was driven by hyperglycemia as disease susceptibility could be reversed with insulin treatment ([@B41]). These findings are consistent with studies of patients infected with highly pathogenic avian influenza, whereby hyperglycemia was associated with a fatal outcome ([@B61]). Interestingly, in a mouse model of type II diabetes, susceptibility to influenza was associated with an impairment in the recruitment of macrophages to the lung ([@B23]). However, whether this phenotype was driven by hyperglycemia or other physiological changes associated with diabetes remains to be determined. Hyperglycemia may also affect pulmonary function such that influenza virus-induced respiratory dysfunction is exacerbated in patients with diabetes. In animal models of disease, diabetes is associated with numerous structural changes to the lung including augmented permeability of the vasculature and a collapsed alveolar epithelium ([@B37]). In patients with diabetes, there is also a significant reduction in forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), and this impaired pulmonary function is significantly associated with raised plasma glucose concentration ([@B27]; [@B64]). Finally, it is important to recognize that during influenza virus pandemics of the last century (including the 2009 H1N1 pandemic) the majority of fatalities were the result of secondary bacterial infections, rather than primary viral pneumonia ([@B46]). Elevated airway glucose concentrations can increase the replication of respiratory bacterial pathogens ([@B14]), suggesting that patients with diabetes may have increased bacterial outgrowth after an influenza virus infection. However, to the best of our knowledge, there have been no large-scale clinical studies investigating the association between influenza severity (and the acquisition or development of any associated secondary bacterial infection) and hyperglycemia in patients with diabetes. Thus, at present, the role of hyperglycemia in the pathogenesis of influenza virus remains unclear.

A Role for Glycemic Oscillations
================================

In the context of vascular complications of diabetes (e.g., cardiovascular disease), there is a growing body of evidence indicating that glucose variability is an important contributing factor to disease development ([@B19]). In healthy individuals, blood glucose levels are kept within a narrow range of 4.4--6.7 mmol/L, including small and short-lived post-prandial peaks ([@B44]). In the setting of impaired glucose tolerance, glucose fluctuations become greater and more frequent ([@B5]). Blood glucose variability generally refers to hour-to-hour or day-to-day oscillations, but may also refer to month-to-month or even year-to-year changes. Glycemic variability is induced by many different factors including consuming a meal, changes in exercise, weight, medication, diet, and sleep patterns ([@B9]). As hyperglycemia is typically measured by a patient's HbA1c, individuals with steady-state and oscillating glucose levels are generally not differentiated in the clinic, making prevalence estimates difficult to obtain. However, it is clear from clinical studies that the extent to which these glucose fluctuations occur differs greatly from patient to patient ([@B32]).

There is now a growing body of evidence showing that glycemic oscillations play an important role in endothelial dysfunction, irrespective of HbA1c levels ([@B42]; [@B39]; [@B3]; [@B7]). For example, patients with type 2 diabetes that had blood glucose levels oscillating between 15 and 5 mmol/l every 6 h for 24 h had a significant increase in endothelial dysfunction relative to diabetic patients exposed to continuous 10 mmol/l glucose ([@B7]). *In vitro*, human umbilical endothelial cells (HUVECs) exposed to oscillating glucose have an increased level of apoptosis compared to HUVECs exposed to constant high levels of glucose ([@B39]). Similarly, human endothelial cells exposed to intermittent high glucose had increased expression of ICAM-1, VCAM-1, VEGF, high mobility group box 1 (HMGB1), IL-8, NF-κB and E-selectin relative to endothelial cells exposed to stable high glucose ([@B38]; [@B34]). This is consistent with studies demonstrating increased monocyte adhesion to endothelial cells in rats exposed to glucose fluctuations relative to stable hyperglycemia ([@B3]).

Endothelial cells, whilst not the primary target of influenza virus in humans, play an important role in disease pathogenesis ([@B52]; [@B50], [@B48], [@B47]). During severe influenza virus infection, pulmonary endothelial cells produce cytokines which drive pulmonary lesions and mortality ([@B52]). In addition to mediating cytokine production, endothelial cells also indirectly control the inflammatory response in the lung during influenza virus infection via the expression of adhesion molecules (e.g., E-selectin, P-selectin, ICAM1, and VCAM1) ([@B48]). Overexpression of these adhesion molecules is thought to impair pulmonary function during influenza virus infection by allowing the uncontrolled extravasation of leukocytes in the alveolus ([@B35]; [@B48]). These leukocytes can in turn damage the lung and impair respiratory function ([@B48]). Given that glycemic oscillations are known to induce endothelial cytokine production ([@B38]; [@B34]) and enhance the expression of endothelial adhesions ([@B38]; [@B34]), it is tempting to speculate that glycemic variability augments the severity of influenza, at least in part, via effects on pulmonary endothelial cells.

Conclusion and Future Directions
================================

Diabetes is one of the world's fastest growing chronic diseases, whereby the proportion of adults with diabetes is projected to increase from 9 to 10% by the year 2040 ([@B22]). With advancements in awareness, detection, and management of the disease, the average life expectancy of patients with diabetes is increasing ([@B31]; [@B16]; [@B20]). Thus, the number of individuals living with long-term complications is enhanced. Given this growing prevalence of diabetes and the increased window of opportunity for influenza virus infection, it is surprising that there are only few published studies in this field. It is therefore imperative that we dedicate research efforts to understanding how diabetes can increase the severity of influenza.

This includes delineating the role of other underlying comorbidities, hyperglycemia and glycemic oscillations in disease development and severity. Moreover, whilst type 1 and type 2 diabetes share a common symptom, i.e., hyperglycemia, they are vastly different in disease pathogenesis and, potentially, in their susceptibility to complications including influenza virus. Therefore, future studies would benefit from studying the development and severity of influenza in both type 1 and type 2 diabetes mellitus. This research will prove vital in mitigating the burden of future influenza epidemics and pandemics.
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